<ul><li>Sam Altman, CEO of OpenAI, is spearheading a $180 million initiative through Retro Biosciences to extend human lifespan by a decade.</li><li>Collaborating with scientist Joe Betts-LaCroix, Retro Biosciences explores cutting-edge methods like autophagy enhancement, cellular reprogramming, and plasma therapy. Altman's pivot from AI to biotech signifies a broader mission to address existential threats.</li><li>Amidst competition from tech giants like Bezos and Thiel in the longevity race, Altman's vision aligns with societal well-being. As Retro Biosciences pushes boundaries, Altman's endeavor could reshape healthcare, ushering in an era where longevity isn't just a dream but a tangible reality.</li></ul>

Sam Altman invested $180 million into a company trying to delay death

Discover more